“Despite intense worldwide research efforts over decades, treatment of cystic fibrosis to date still represents a huge unmet clinical need,“ stated Michael Thompson, Ph.D, co-founder and CEO of DyNAbind. “We are happy to offer our proprietary DEL platform to the Center for Cardiavascular Science to help improving the life of these patients. We’re looking forward to working with Professor Scott Webster and Dr Robert Gray and their teams on this important project.”
Professor Scott Webster, Professor of Medicines Discovery, Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh said: “We are delighted to be working with DyNabind. This exciting collaboration offers an opportunity to deploy the DyNAbind platform to search for novel small molecule modulators as starting points for a potential new medicine. Molecules discovered as part of this collaboration will be profiled in models of disease to identify potential medicines for patients with cystic fibrosis.”
Dr Robert Gray, NRS Senior Fellow and Physician Scientist at the University of Edinburgh Centre for Inflammation Research said: “Inflammation is a process at the centre of Cystic Fibrosis lung disease, but we have no specific anti-inflammatory drugs to treat it. This new collaboration with DyNAbind is the first major step towards developing new drugs that target inflammation in Cystic Fibrosis.”
Financial terms of the collaboration agreement were not disclosed.
DyNAbind GmbH is a privately held company based in Dresden, Germany, offering a nextgeneration platform of DNA-Encoded Library (DEL) technologies for drug discovery and optimization. DyNAbind’s founders have years of experience in developing and working with DEL technologies, which has driven the development of the novel Dynamic Library platform.
By specifically tuning a DNA architecture for transient interactions, fragment molecules in the library dynamically self-assemble and rearrange themselves into ideal binding structures, offering dramatically improved signal-to-noise ratios and reduced false positive hit rates. Follow-up quantitative hit validation can begin without the need for hit resynthesis, allowing meaningful results to arrive in days instead of months.
Our entire team at DyNAbind is dedicated to working with our partners to develop and implement the most effective discovery and optimization programs for any drug target.
Whether your program is coming from the pharma, biotech or academic sector, we’re motivated to help you find the best path to higher-quality, more relevant medicinal chemistry starting points.
About the Centre for Cardiovascular Science at The Queen's Medical Research Institute, University of Edinburgh
The Centre for Cardiovascular Science is a world-leading centre of excellence in the University of Edinburgh that integrates discovery, translational and clinical cardiovascular research to transform the diagnosis, treatment and management of people with heart and circulatory diseases. We are working with local, national and international partners and funders to develop solutions to our research challenges with regional and global impact. For further information please visit the University’s website at: http://edin.ac/2dqzzUB